<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35773551</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1102</StartPage><EndPage>1118</EndPage><MedlinePgn>1102-1118</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-022-01262-3</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that primarily affects motor neurons and causes muscle atrophy, paralysis, and death. While a great deal of progress has been made in deciphering the underlying pathogenic mechanisms, no effective treatments for the disease are currently available. This is mainly due to the high degree of complexity and heterogeneity that characterizes the disease. Over the last few decades of research, alterations to bioenergetic and metabolic homeostasis have emerged as a common denominator across many different forms of ALS. These alterations are found at the cellular level (e.g., mitochondrial dysfunction and impaired expression of monocarboxylate transporters) and at the systemic level (e.g., low BMI and hypermetabolism) and tend to be associated with survival or disease outcomes in patients. Furthermore, an increasing amount of preclinical evidence and some promising clinical evidence suggests that targeting energy metabolism could be an effective therapeutic strategy. This review examines the evidence both for and against these ALS-associated metabolic alterations and highlights potential avenues for therapeutic intervention.</AbstractText><CopyrightInformation>&#xa9; 2022. The American Society for Experimental NeuroTherapeutics, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, JHN Bldg., 4th floor, room 416, Philadelphia, PA, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trotti</LastName><ForeName>Davide</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6338-6404</Identifier><AffiliationInfo><Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Department of Neuroscience, Thomas Jefferson University, 900 Walnut Street, JHN Bldg., 4th floor, room 416, Philadelphia, PA, 19107, USA. davide.trotti@jefferson.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 NS118838</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057882</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ATP</Keyword><Keyword MajorTopicYN="N">Glucose</Keyword><Keyword MajorTopicYN="N">Glycolysis</Keyword><Keyword MajorTopicYN="N">Lipids</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35773551</ArticleId><ArticleId IdType="pmc">PMC9587161</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01262-3</ArticleId><ArticleId IdType="pii">10.1007/s13311-022-01262-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, Fratta P, Traynor BJ, Chia R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts ME, Pocock R, Claudianos C. Brain energy and oxygen metabolism: emerging role in normal function and disease. Front Mol Neurosci. 2018;11:216. doi: 10.3389/fnmol.2018.00216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00216</ArticleId><ArticleId IdType="pmc">PMC6023993</ArticleId><ArticleId IdType="pubmed">29988368</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, et al. Effect of Presymptomatic body mass index and consumption of fat and alcohol on amyotrophic lateral sclerosis. JAMA Neurol. 2015;72:1155&#x2013;1162. doi: 10.1001/jamaneurol.2015.1584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1584</ArticleId><ArticleId IdType="pubmed">26280944</ArticleId></ArticleIdList></Reference><Reference><Citation>Popuri K, et al. FDG-PET in presymptomatic C9orf72 mutation carriers. Neuroimage Clin. 2021;31:102687. doi: 10.1016/j.nicl.2021.102687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2021.102687</ArticleId><ArticleId IdType="pmc">PMC8170157</ArticleId><ArticleId IdType="pubmed">34049163</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharaoh G, et al. Metabolic and stress response changes precede disease onset in the spinal cord of mutant SOD1 ALS mice. Front Neurosci. 2019;13:487. doi: 10.3389/fnins.2019.00487.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00487</ArticleId><ArticleId IdType="pmc">PMC6554287</ArticleId><ArticleId IdType="pubmed">31213966</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82:628&#x2013;634. doi: 10.1136/jnnp.2010.211474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.211474</ArticleId><ArticleId IdType="pubmed">21097551</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G, et al. Adipokines, C-reactive protein and amyotrophic lateral sclerosis - results from a population- based ALS registry in Germany. Sci Rep. 2017;7:4374. doi: 10.1038/s41598-017-04706-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04706-5</ArticleId><ArticleId IdType="pmc">PMC5491500</ArticleId><ArticleId IdType="pubmed">28663573</ArticleId></ArticleIdList></Reference><Reference><Citation>van Mantgem MRJ, et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020;91:867&#x2013;75. 10.1136/jnnp-2020-322909.</Citation><ArticleIdList><ArticleId IdType="pubmed">32576612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei QQ, et al. Early weight instability is associated with cognitive decline and poor survival in amyotrophic lateral sclerosis. Brain Res Bull. 2021;171:10&#x2013;15. doi: 10.1016/j.brainresbull.2021.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2021.02.022</ArticleId><ArticleId IdType="pubmed">33636227</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, et al. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:91&#x2013;96. doi: 10.1080/14660820050515386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820050515386</ArticleId><ArticleId IdType="pubmed">11467055</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, et al. Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019;90:666&#x2013;673. doi: 10.1136/jnnp-2018-319611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId><ArticleId IdType="pubmed">30630957</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm T, et al. Severe loss of appetite in amyotrophic lateral sclerosis patients: online self-assessment study. Interact J Med Res. 2013;2:e8. doi: 10.2196/ijmr.2463.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/ijmr.2463</ArticleId><ArticleId IdType="pmc">PMC3632382</ArticleId><ArticleId IdType="pubmed">23608722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo ST, et al. Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:497&#x2013;505. doi: 10.1080/21678421.2019.1621346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1621346</ArticleId><ArticleId IdType="pubmed">31144522</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezoian T, et al. Loss of appetite in amyotrophic lateral sclerosis is associated with weight loss and decreased calorie consumption independent of dysphagia. Muscle Nerve. 2020;61:218&#x2013;242. doi: 10.1002/mus.26749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26749</ArticleId><ArticleId IdType="pubmed">31650547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges M, et al. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:1033&#x2013;1041. doi: 10.1136/jnnp-2017-316382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316382</ArticleId><ArticleId IdType="pubmed">28596251</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer D, et al. Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients. Transl Neurodegener. 2021;10:17. doi: 10.1186/s40035-021-00241-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00241-6</ArticleId><ArticleId IdType="pmc">PMC8168014</ArticleId><ArticleId IdType="pubmed">34059131</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabery S, et al. Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2021;47:979&#x2013;989. doi: 10.1111/nan.12709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12709</ArticleId><ArticleId IdType="pubmed">33755993</ArticleId></ArticleIdList></Reference><Reference><Citation>Saper CB, Lowell BB. The hypothalamus. Curr Biol. 2014;24:R1111&#x2013;1116. doi: 10.1016/j.cub.2014.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2014.10.023</ArticleId><ArticleId IdType="pubmed">25465326</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, et al. Genome-wide meta-analysis finds the ACSL5-ZDHHC6 locus is associated with ALS and links weight loss to the disease genetics. Cell Rep. 2020;33:108323. doi: 10.1016/j.celrep.2020.108323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108323</ArticleId><ArticleId IdType="pmc">PMC7610013</ArticleId><ArticleId IdType="pubmed">33113361</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar A, et al. Acyl-CoA synthetase long-chain 5 genotype is associated with body composition changes in response to lifestyle interventions in postmenopausal women with overweight and obesity: a genetic association study on cohorts Montreal-Ottawa New Emerging Team, and Complications Associated with Obesity. BMC Med Genet. 2016;17:56. doi: 10.1186/s12881-016-0320-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12881-016-0320-4</ArticleId><ArticleId IdType="pmc">PMC4982019</ArticleId><ArticleId IdType="pubmed">27515448</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with amyotrophic lateral sclerosis: Relation to the proximity of death. Am J Clin Nutr. 1996;63:130&#x2013;137. doi: 10.1093/ajcn/63.1.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/63.1.130</ArticleId><ArticleId IdType="pubmed">8604660</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74:328&#x2013;334. doi: 10.1093/ajcn/74.3.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256:1236&#x2013;1242. doi: 10.1007/s00415-009-5100-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5100-z</ArticleId><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaisman N, et al. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci. 2009;279:26&#x2013;29. doi: 10.1016/j.jns.2008.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.12.027</ArticleId><ArticleId IdType="pubmed">19185883</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus P, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2018;25:97&#x2013;104. doi: 10.1111/ene.13468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13468</ArticleId><ArticleId IdType="pubmed">28940704</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2018-318428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318428</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayemendy P, et al. Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects. J Neurol Sci. 2021;420:117257. doi: 10.1016/j.jns.2020.117257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117257</ArticleId><ArticleId IdType="pubmed">33290920</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Rene F, de Aguilar JLG, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA. 2004;101:11159&#x2013;64. 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter C, et al. Uncoupled skeletal muscle mitochondria contribute to hypermetabolism in severely burned adults. Am J Physiol Endocrinol Metab. 2014;307:E462&#x2013;467. doi: 10.1152/ajpendo.00206.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00206.2014</ArticleId><ArticleId IdType="pmc">PMC4154069</ArticleId><ArticleId IdType="pubmed">25074988</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae JS, Simon NG, Menon P, Vucic S, Kiernan MC. The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol. 2013;9:65&#x2013;74. doi: 10.3988/jcn.2013.9.2.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2013.9.2.65</ArticleId><ArticleId IdType="pmc">PMC3633193</ArticleId><ArticleId IdType="pubmed">23626643</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53:1059&#x2013;1063. doi: 10.1212/WNL.53.5.1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.5.1059</ArticleId><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, et al. Population-based evidence that survival in amyotrophic lateral sclerosis is related to weight loss at diagnosis. Neurodegener Dis. 2016;16:225&#x2013;235. doi: 10.1159/000442444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000442444</ArticleId><ArticleId IdType="pubmed">26866503</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, et al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. 2017;32:901&#x2013;908. doi: 10.1007/s10654-017-0318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly EJ, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:205&#x2013;211. doi: 10.3109/21678421.2012.735240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.735240</ArticleId><ArticleId IdType="pmc">PMC3615420</ArticleId><ArticleId IdType="pubmed">23134505</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T, et al. Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study. J Neurol. 2019;266:1412&#x2013;1420. doi: 10.1007/s00415-019-09276-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09276-2</ArticleId><ArticleId IdType="pubmed">30868220</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, et al. Body mass index and amyotrophic lateral sclerosis: a study of US military veterans. Am J Epidemiol. 2017;185:362&#x2013;371. doi: 10.1093/aje/kww140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kww140</ArticleId><ArticleId IdType="pmc">PMC5860019</ArticleId><ArticleId IdType="pubmed">28158443</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly EJ, et al. Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:396&#x2013;406. doi: 10.1080/21678421.2018.1452944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1452944</ArticleId><ArticleId IdType="pmc">PMC6423444</ArticleId><ArticleId IdType="pubmed">29658324</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, et al. Prognostic factors in ALS: a comparison between Germany and China. J Neurol. 2019;266:1516&#x2013;1525. doi: 10.1007/s00415-019-09290-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09290-4</ArticleId><ArticleId IdType="pubmed">30923935</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102. doi: 10.1038/s41467-019-13668-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13668-3</ArticleId><ArticleId IdType="pmc">PMC6941980</ArticleId><ArticleId IdType="pubmed">31900386</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart MN, Cancilla PA, Frommes S, Hirano A. Anterior horn cell degeneration and bunina-Type inclusions associated with dementia. Acta Neuropathol. 1977;38:225&#x2013;228. doi: 10.1007/BF00688069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00688069</ArticleId><ArticleId IdType="pubmed">197771</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Hirai S, Shoji M, Senoh T, Yamazaki T. Axonal swellings in the corticospinal tracts in amyotrophic lateral sclerosis. Acta Neuropathol. 1990;80:222&#x2013;226. doi: 10.1007/BF00308929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308929</ArticleId><ArticleId IdType="pubmed">2202191</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iwata M. Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. Neurosci Lett. 1996;204:53&#x2013;56. doi: 10.1016/0304-3940(96)12314-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(96)12314-4</ArticleId><ArticleId IdType="pubmed">8929976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MJ, Suh YL. Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastruct Pathol. 2002;26:3&#x2013;7. doi: 10.1080/01913120252934260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01913120252934260</ArticleId><ArticleId IdType="pubmed">12028652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2007;66:10&#x2013;16. doi: 10.1097/nen.0b013e31802c396b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31802c396b</ArticleId><ArticleId IdType="pubmed">17204932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15:e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto MC, Gurney ME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol. 1994;146:1271&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887498</ArticleId><ArticleId IdType="pubmed">7992831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci. 1998;18:3241&#x2013;3250. doi: 10.1523/JNEUROSCI.18-09-03241.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-09-03241.1998</ArticleId><ArticleId IdType="pmc">PMC6792665</ArticleId><ArticleId IdType="pubmed">9547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Szelechowski M, et al. Metabolic reprogramming in amyotrophic lateral sclerosis. Sci Rep. 2018;8:3953. doi: 10.1038/s41598-018-22318-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22318-5</ArticleId><ArticleId IdType="pmc">PMC5834494</ArticleId><ArticleId IdType="pubmed">29500423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkinezos IG, et al. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J Neurosci. 2005;25:164&#x2013;172. doi: 10.1523/JNEUROSCI.3829-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3829-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725219</ArticleId><ArticleId IdType="pubmed">15634778</ArticleId></ArticleIdList></Reference><Reference><Citation>Stribl C, et al. Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43. J Biol Chem. 2014;289:10769&#x2013;10784. doi: 10.1074/jbc.M113.515940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.515940</ArticleId><ArticleId IdType="pmc">PMC4036193</ArticleId><ArticleId IdType="pubmed">24515116</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J, Cortez C, Gan WB, Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum Mol Genet. 2014;23:1413&#x2013;1424. doi: 10.1093/hmg/ddt528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt528</ArticleId><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, et al. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun. 2016;7:10465. doi: 10.1038/ncomms10465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10465</ArticleId><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies FM, et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain. 2002;125:1522&#x2013;1533. doi: 10.1093/brain/awf167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf167</ArticleId><ArticleId IdType="pubmed">12077002</ArticleId></ArticleIdList></Reference><Reference><Citation>Coussee E, et al. G37R SOD1 mutant alters mitochondrial complex I activity, Ca(2+) uptake and ATP production. Cell Calcium. 2011;49:217&#x2013;225. doi: 10.1016/j.ceca.2011.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2011.02.004</ArticleId><ArticleId IdType="pubmed">21388680</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, et al. Mitochondrial dysfunction in human TDP-43 transfected NSC34 cell lines and the protective effect of dimethoxy curcumin. Brain Res Bull. 2012;89:185&#x2013;190. doi: 10.1016/j.brainresbull.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2012.09.005</ArticleId><ArticleId IdType="pubmed">22986236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum Mol Genet. 2013;22:4706&#x2013;4719. doi: 10.1093/hmg/ddt319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt319</ArticleId><ArticleId IdType="pmc">PMC3820133</ArticleId><ArticleId IdType="pubmed">23827948</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, et al. FUS interacts with HSP60 to promote mitochondrial damage. PLoS Genet. 2015;11:e1005357. doi: 10.1371/journal.pgen.1005357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1005357</ArticleId><ArticleId IdType="pmc">PMC4559378</ArticleId><ArticleId IdType="pubmed">26335776</ArticleId></ArticleIdList></Reference><Reference><Citation>Tradewell ML, et al. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum Mol Genet. 2012;21:136&#x2013;149. doi: 10.1093/hmg/ddr448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr448</ArticleId><ArticleId IdType="pubmed">21965298</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesto E, et al. Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathol Commun. 2016;4:47. doi: 10.1186/s40478-016-0316-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0316-5</ArticleId><ArticleId IdType="pmc">PMC4858818</ArticleId><ArticleId IdType="pubmed">27151080</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, et al. C9orf72 Hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia. Stem Cells. 2016;34:2063&#x2013;2078. doi: 10.1002/stem.2388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2388</ArticleId><ArticleId IdType="pmc">PMC4979662</ArticleId><ArticleId IdType="pubmed">27097283</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong K, et al. Full-length TDP-43 and its C-terminal fragments activate mitophagy in NSC34 cell line. Neurosci Lett. 2012;530:144&#x2013;149. doi: 10.1016/j.neulet.2012.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2012.10.003</ArticleId><ArticleId IdType="pubmed">23063673</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalila B, et al. Enhancing mitofusin/marf ameliorates neuromuscular dysfunction in drosophila models of TDP-43 proteinopathies. Neurobiol Aging. 2017;54:71&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">28324764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22:869&#x2013;878. doi: 10.1038/nm.4130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4130</ArticleId><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins CMJ, Jung C, Ding H, Xu Z. Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci. 2002;22:1&#x2013;6. doi: 10.1523/JNEUROSCI.22-06-j0001.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-06-j0001.2002</ArticleId><ArticleId IdType="pmc">PMC6758252</ArticleId><ArticleId IdType="pubmed">11886899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi M, et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem. 2002;277:29626&#x2013;29633. doi: 10.1074/jbc.M203065200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M203065200</ArticleId><ArticleId IdType="pubmed">12050154</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayvergiya C, Beal MF, Buck J, Manfredi G. Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci. 2005;25:2463&#x2013;2470. doi: 10.1523/JNEUROSCI.4385-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4385-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725162</ArticleId><ArticleId IdType="pubmed">15758154</ArticleId></ArticleIdList></Reference><Reference><Citation>Vande Velde C, Miller TM, Cashman NR, Cleveland DW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci USA. 2008;105:4022&#x2013;7. 10.1073/pnas.0712209105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268797</ArticleId><ArticleId IdType="pubmed">18296640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, et al. C9orf72 regulates energy homeostasis by stabilizing mitochondrial complex I assembly. Cell Metab. 2021;33:531&#x2013;46 e539. 10.1016/j.cmet.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579819</ArticleId><ArticleId IdType="pubmed">33545050</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, et al. Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways. Acta Neuropathol. 2016;132:175&#x2013;196. doi: 10.1007/s00401-016-1575-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1575-8</ArticleId><ArticleId IdType="pmc">PMC4947123</ArticleId><ArticleId IdType="pubmed">27164932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, et al. Poly(GR) in C9ORF72-Related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 2016;92:383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, et al. Altered MICOS Morphology and mitochondrial ion homeostasis contribute to poly(GR) toxicity associated with C9-ALS/FTD. Cell Rep. 2020;32:107989. doi: 10.1016/j.celrep.2020.107989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107989</ArticleId><ArticleId IdType="pmc">PMC7433775</ArticleId><ArticleId IdType="pubmed">32755582</ArticleId></ArticleIdList></Reference><Reference><Citation>Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death. Ann Neurol. 1999;46:787&#x2013;790. doi: 10.1002/1531-8249(199911)46:5&lt;787::AID-ANA17&gt;3.0.CO;2-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199911)46:5&lt;787::AID-ANA17&gt;3.0.CO;2-8</ArticleId><ArticleId IdType="pubmed">10553999</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann FR, Manfredi G, Mawrin C, Beal F, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem. 2002;80:616&#x2013;625. doi: 10.1046/j.0022-3042.2001.00731.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2001.00731.x</ArticleId><ArticleId IdType="pubmed">11841569</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaniz-Laguna A, et al. Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: a temporal study in man. Exp Neurol. 2006;198:25&#x2013;30. doi: 10.1016/j.expneurol.2005.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.07.020</ArticleId><ArticleId IdType="pubmed">16126198</ArticleId></ArticleIdList></Reference><Reference><Citation>Crugnola V, et al. Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch Neurol. 2010;67:849&#x2013;854. doi: 10.1001/archneurol.2010.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.128</ArticleId><ArticleId IdType="pubmed">20625092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann F, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci. 1998;156:65&#x2013;72. doi: 10.1016/S0022-510X(98)00008-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00008-2</ArticleId><ArticleId IdType="pubmed">9559989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C, Higgins CMJ, Xu Z. Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem. 2002;83:535&#x2013;545. doi: 10.1046/j.1471-4159.2002.01112.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01112.x</ArticleId><ArticleId IdType="pubmed">12390515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, et al. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci USA. 2006;103:13860&#x2013;13865. doi: 10.1073/pnas.0605814103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605814103</ArticleId><ArticleId IdType="pmc">PMC1557633</ArticleId><ArticleId IdType="pubmed">16945901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiasi P, Hosseinkhani S, Noori A, Nafissi S, Khajeh K. Mitochondrial complex I deficiency and ATP/ADP ratio in lymphocytes of amyotrophic lateral sclerosis patients. Neurol Res. 2012;34:297&#x2013;303. doi: 10.1179/1743132812Y.0000000012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1743132812Y.0000000012</ArticleId><ArticleId IdType="pubmed">22450425</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasnianski A, et al. Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies. Brain. 2005;128:1870&#x2013;1876. doi: 10.1093/brain/awh540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh540</ArticleId><ArticleId IdType="pubmed">15901649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling AC, Schulz JB, Brown RH, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 1993;61:2322&#x2013;2325. doi: 10.1111/j.1471-4159.1993.tb07478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb07478.x</ArticleId><ArticleId IdType="pubmed">8245985</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne SE, et al. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem. 1998;71:281&#x2013;287. doi: 10.1046/j.1471-4159.1998.71010281.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1998.71010281.x</ArticleId><ArticleId IdType="pubmed">9648876</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R, et al. ALS/FTD-associated FUS activates GSK-3beta to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations. EMBO Rep. 2016;17:1326&#x2013;1342. doi: 10.15252/embr.201541726.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201541726</ArticleId><ArticleId IdType="pmc">PMC5007559</ArticleId><ArticleId IdType="pubmed">27418313</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzino G, et al. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017;2017:8416763. doi: 10.1155/2017/8416763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/8416763</ArticleId><ArticleId IdType="pmc">PMC5551541</ArticleId><ArticleId IdType="pubmed">28819546</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Sun L, Chen X, Zhang D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res. 2013;8:2003&#x2013;2014. doi: 10.3969/j.issn.1673-5374.2013.21.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1673-5374.2013.21.009</ArticleId><ArticleId IdType="pmc">PMC4145906</ArticleId><ArticleId IdType="pubmed">25206509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha-Oliveira T, et al. Oxidative stress in amyotrophic lateral sclerosis: Pathophysiology and opportunities for pharmacological intervention. Oxid Med Cell Longev. 2020;2020:5021694. doi: 10.1155/2020/5021694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5021694</ArticleId><ArticleId IdType="pmc">PMC7683149</ArticleId><ArticleId IdType="pubmed">33274002</ArticleId></ArticleIdList></Reference><Reference><Citation>Vielhaber S, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain. 2000;123:1339&#x2013;1348. doi: 10.1093/brain/123.7.1339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.7.1339</ArticleId><ArticleId IdType="pubmed">10869047</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotroph Lateral Scler. 2006;7:241&#x2013;245. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36:587&#x2013;597. doi: 10.1016/j.tins.2013.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.07.001</ArticleId><ArticleId IdType="pmc">PMC3900881</ArticleId><ArticleId IdType="pubmed">23968694</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawada K, Iwamoto M, Sakai Y. Mechanisms underlying (18)F-fluorodeoxyglucose accumulation in colorectal cancer. World J Radiol. 2016;8:880&#x2013;886. doi: 10.4329/wjr.v8.i11.880.</Citation><ArticleIdList><ArticleId IdType="doi">10.4329/wjr.v8.i11.880</ArticleId><ArticleId IdType="pmc">PMC5120247</ArticleId><ArticleId IdType="pubmed">27928469</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol. 1987;22:580&#x2013;586. doi: 10.1002/ana.410220504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410220504</ArticleId><ArticleId IdType="pubmed">3501273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand. 1992;85:81&#x2013;89. doi: 10.1111/j.1600-0404.1992.tb04003.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1992.tb04003.x</ArticleId><ArticleId IdType="pubmed">1574993</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurol. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71:553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, et al. Early and progressive impairment of spinal blood flow-glucose metabolism coupling in motor neuron degeneration of ALS model mice. J Cereb Blood Flow Metab. 2012;32:456&#x2013;467. doi: 10.1038/jcbfm.2011.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2011.155</ArticleId><ArticleId IdType="pmc">PMC3293114</ArticleId><ArticleId IdType="pubmed">22068226</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vocht J, et al. Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion. JAMA Neurol. 2020;77:1008&#x2013;1017. doi: 10.1001/jamaneurol.2020.1087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1087</ArticleId><ArticleId IdType="pmc">PMC7417970</ArticleId><ArticleId IdType="pubmed">32421156</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald TS, Kumar V, Fung JN, Woodruff TM, Lee JD. Glucose clearance and uptake is increased in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis through an insulin-independent mechanism. FASEB J. 2021;35:e21707. doi: 10.1096/fj.202002450R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202002450R</ArticleId><ArticleId IdType="pubmed">34118098</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulton KR, Rossi ML. Peripheral nerve protein glycation and muscle fructolysis: Evidence of abnormal carbohydrate metabolism in ALS. Funct Neurol. 1993;8:33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">8330752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XS, Simmons Z, Liu W, Boyer PJ, Connor JR. Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph Lateral Scler. 2006;7:201&#x2013;210. doi: 10.1080/17482960600947689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600947689</ArticleId><ArticleId IdType="pubmed">17127558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer CW, Torrisi A, Pantelidou M, Santama N, Cavallaro S. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genom. 2007;8:26. doi: 10.1186/1471-2164-8-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-8-26</ArticleId><ArticleId IdType="pmc">PMC1796866</ArticleId><ArticleId IdType="pubmed">17244347</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman R, et al. Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions. Neuropathol Appl Neurobiol. 2015;41:201&#x2013;226. doi: 10.1111/nan.12147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12147</ArticleId><ArticleId IdType="pmc">PMC4329387</ArticleId><ArticleId IdType="pubmed">24750211</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, et al. Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc Natl Acad Sci USA. 2013;110:10812&#x2013;10817. doi: 10.1073/pnas.1308421110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1308421110</ArticleId><ArticleId IdType="pmc">PMC3696768</ArticleId><ArticleId IdType="pubmed">23754387</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SP, et al. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain. 2019;142:3771&#x2013;3790. doi: 10.1093/brain/awz302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz302</ArticleId><ArticleId IdType="pmc">PMC6906594</ArticleId><ArticleId IdType="pubmed">31647549</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena GN, et al. Metabolomic analysis reveals increased aerobic glycolysis and amino acid deficit in a cellular model of amyotrophic lateral sclerosis. Mol Neurobiol. 2016;53:2222&#x2013;2240. doi: 10.1007/s12035-015-9165-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9165-7</ArticleId><ArticleId IdType="pmc">PMC4823370</ArticleId><ArticleId IdType="pubmed">25963727</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SP, et al. Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. Neurobiol Aging. 2014;35:1499&#x2013;1509. doi: 10.1016/j.neurobiolaging.2013.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.025</ArticleId><ArticleId IdType="pubmed">24439480</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife. 2019;8. 10.7554/eLife.45114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury GM, et al. Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus. J Cereb Blood Flow Metab. 2008;28:1892&#x2013;1897. doi: 10.1038/jcbfm.2008.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2008.78</ArticleId><ArticleId IdType="pmc">PMC2739056</ArticleId><ArticleId IdType="pubmed">18628780</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel B, Green O, Viskind O, Gruzman A. Riluzole increases the rate of glucose transport in L6 myotubes and NSC-34 motor neuron-like cells via AMPK pathway activation. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:434&#x2013;443. doi: 10.3109/21678421.2013.808226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.808226</ArticleId><ArticleId IdType="pubmed">23834207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lago-Baldaia I, Fernandes VM, Ackerman SD. More than mortar: glia as architects of nervous system development and disease. Front Cell Dev Biol. 2020;8:611269. doi: 10.3389/fcell.2020.611269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.611269</ArticleId><ArticleId IdType="pmc">PMC7767919</ArticleId><ArticleId IdType="pubmed">33381506</ArticleId></ArticleIdList></Reference><Reference><Citation>Machler P, et al. In vivo evidence for a lactate gradient from astrocytes to neurons. Cell Metab. 2016;23:94&#x2013;102. doi: 10.1016/j.cmet.2015.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2015.10.010</ArticleId><ArticleId IdType="pubmed">26698914</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki A, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell. 2011;144:810&#x2013;823. doi: 10.1016/j.cell.2011.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.02.018</ArticleId><ArticleId IdType="pmc">PMC3073831</ArticleId><ArticleId IdType="pubmed">21376239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487:443&#x2013;448. doi: 10.1038/nature11314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11314</ArticleId><ArticleId IdType="pmc">PMC3408792</ArticleId><ArticleId IdType="pubmed">22801498</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16:571&#x2013;579. doi: 10.1038/nn.3357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3357</ArticleId><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain. 2013;136:471&#x2013;482. doi: 10.1093/brain/aws339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws339</ArticleId><ArticleId IdType="pmc">PMC3572934</ArticleId><ArticleId IdType="pubmed">23378219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, et al. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain. 2011;134:2627&#x2013;2641. doi: 10.1093/brain/awr193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr193</ArticleId><ArticleId IdType="pmc">PMC3170534</ArticleId><ArticleId IdType="pubmed">21908873</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, et al. MCT1 deletion in oligodendrocyte lineage cells causes late-onset hypomyelination and axonal degeneration. Cell Rep. 2021;34:108610. doi: 10.1016/j.celrep.2020.108610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108610</ArticleId><ArticleId IdType="pmc">PMC8020895</ArticleId><ArticleId IdType="pubmed">33440165</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinke J, Tyler HR. The association of amyotrophic lateral sclerosis (motor neuron disease) and carbohydrate intolerance, a clinical study. Metabolism. 1964;13:1376&#x2013;1381. doi: 10.1016/0026-0495(64)90158-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0026-0495(64)90158-1</ArticleId><ArticleId IdType="pubmed">14241228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionasescu V, Luca N. Studies on carbohydrate metabolism in amyotrophic lateral sclerosis and hereditary proximal spinal musclar atrophy. Acta Neurol Scand. 1964;40:47&#x2013;57. doi: 10.1111/j.1600-0404.1964.tb04265.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1964.tb04265.x</ArticleId><ArticleId IdType="pubmed">14108417</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes ET, Perurena OH, Festoff BW, Jorgensen R, Moore WV. Insulin resistance in amyotrophic lateral sclerosis. J Neurol Sci. 1984;63:317&#x2013;324. doi: 10.1016/0022-510X(84)90154-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(84)90154-0</ArticleId><ArticleId IdType="pubmed">6374040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:166&#x2013;171. doi: 10.3109/17482960902822960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902822960</ArticleId><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, et al. Eating peptides: Biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Ann Clin Transl Neurol. 2019;6:486&#x2013;495. doi: 10.1002/acn3.721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.721</ArticleId><ArticleId IdType="pmc">PMC6414477</ArticleId><ArticleId IdType="pubmed">30911572</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: Review of the underlying molecular mechanisms. J Cell Physiol. 2019;234:8152&#x2013;8161. doi: 10.1002/jcp.27603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27603</ArticleId><ArticleId IdType="pubmed">30317615</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, et al. ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol. 2010;17:733&#x2013;739. doi: 10.1111/j.1468-1331.2009.02923.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02923.x</ArticleId><ArticleId IdType="pubmed">20074230</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis - an epidemiologic study. Neurology. 2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings NR, et al. TDP-43, an ALS Linked protein, regulates fat deposition and glucose homeostasis. PLoS One. 2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742534</ArticleId><ArticleId IdType="pubmed">23967244</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K, et al. TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J Clin Invest. 2019;129:3578&#x2013;93. 10.1172/JCI124481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6715357</ArticleId><ArticleId IdType="pubmed">31355778</ArticleId></ArticleIdList></Reference><Reference><Citation>Atilano ML, et al. Enhanced insulin signalling ameliorates C9orf72 hexanucleotide repeat expansion toxicity in Drosophila. Elife. 2021;10. 10.7554/eLife.58565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007214</ArticleId><ArticleId IdType="pubmed">33739284</ArticleId></ArticleIdList></Reference><Reference><Citation>Helkin A, et al. Dyslipidemia part 1&#x2013;review of lipid metabolism and vascular cell physiology. Vasc Endovascular Surg. 2016;50:107&#x2013;118. doi: 10.1177/1538574416628654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1538574416628654</ArticleId><ArticleId IdType="pubmed">26983667</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, et al. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258:613&#x2013;617. doi: 10.1007/s00415-010-5805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:478&#x2013;484. doi: 10.3109/21678421.2015.1062517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062517</ArticleId><ArticleId IdType="pubmed">26161993</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L, et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med. 2015;7:526&#x2013;546. doi: 10.15252/emmm.201404433.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, et al. Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis. Brain Commun. 2020;2:fcaa154. 10.1093/braincomms/fcaa154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677608</ArticleId><ArticleId IdType="pubmed">33241210</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabjerg MS, et al. Downregulating carnitine palmitoyl transferase 1 affects disease progression in the SOD1 G93A mouse model of ALS. Commun Biol. 2021;4:509. doi: 10.1038/s42003-021-02034-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02034-z</ArticleId><ArticleId IdType="pmc">PMC8087699</ArticleId><ArticleId IdType="pubmed">33931719</ArticleId></ArticleIdList></Reference><Reference><Citation>Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 1863;2422&#x2013;2435:2016. doi: 10.1016/j.bbamcr.2016.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2016.01.023</ArticleId><ArticleId IdType="pmc">PMC4967041</ArticleId><ArticleId IdType="pubmed">26828774</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, et al. Medium-chain fatty acids, beta-hydroxybutyric acid and genetic modulation of the carnitine shuttle are protective in a drosophila model of ALS based on TDP-43. Front Mol Neurosci. 2018;11:182. doi: 10.3389/fnmol.2018.00182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00182</ArticleId><ArticleId IdType="pmc">PMC5990617</ArticleId><ArticleId IdType="pubmed">29904341</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YJ, et al. Activation of AMP-activated protein kinase alpha1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. Hum Mol Genet. 2015;24:787&#x2013;801. doi: 10.1093/hmg/ddu497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu497</ArticleId><ArticleId IdType="pubmed">25256353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim MA, et al. Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. J Neurosci. 2012;32:1123&#x2013;1141. doi: 10.1523/JNEUROSCI.6554-10.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6554-10.2012</ArticleId><ArticleId IdType="pmc">PMC3742882</ArticleId><ArticleId IdType="pubmed">22262909</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera ND, et al. Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. PLoS One. 2014;9:e90449. doi: 10.1371/journal.pone.0090449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090449</ArticleId><ArticleId IdType="pmc">PMC3942426</ArticleId><ArticleId IdType="pubmed">24595038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13:1016&#x2013;1023. doi: 10.1038/ncb2329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2329</ArticleId><ArticleId IdType="pmc">PMC3249400</ArticleId><ArticleId IdType="pubmed">21892142</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YJ, Lee LM, Lai HL, Chern Y. Aberrant activation of AMP-activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett. 2015;589:432&#x2013;439. doi: 10.1016/j.febslet.2014.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2014.12.029</ArticleId><ArticleId IdType="pubmed">25592834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One. 2011;6:e24189. doi: 10.1371/journal.pone.0024189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024189</ArticleId><ArticleId IdType="pmc">PMC3164704</ArticleId><ArticleId IdType="pubmed">21909419</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan KS, Mitchem MR, Hogg MC, Prehn JH. &#x201c;Preconditioning&#x201d; with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015;36:1140&#x2013;1150. doi: 10.1016/j.neurobiolaging.2014.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.022</ArticleId><ArticleId IdType="pubmed">25443289</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, et al. Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics. 2014;11:419&#x2013;432. doi: 10.1007/s13311-013-0253-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-013-0253-y</ArticleId><ArticleId IdType="pmc">PMC3996124</ArticleId><ArticleId IdType="pubmed">24414863</ArticleId></ArticleIdList></Reference><Reference><Citation>Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. 2005;280:17187&#x2013;17195. doi: 10.1074/jbc.M501250200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M501250200</ArticleId><ArticleId IdType="pubmed">15749705</ArticleId></ArticleIdList></Reference><Reference><Citation>Thau N, et al. Decreased mRNA expression of PGC-1a and PGC-1a-Yregulated factors in the SOD1-G93A ALS mouse model and in human sporadic ALS. J Neuropathol Exp Neurol. 2012;71:1064&#x2013;1074. doi: 10.1097/NEN.0b013e318275df4b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318275df4b</ArticleId><ArticleId IdType="pubmed">23147503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer H, et al. ALS-causing mutations differentially affect PGC-1alpha expression and function in the brain vs. peripheral tissues. Neurobiol Dis. 2017;97:36&#x2013;45. 10.1016/j.nbd.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">27818323</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KN, Clark JP, Anderson RM. Mitochondrial regulator PGC-1a-modulating the modulator. Curr Opin Endocr Metab Res. 2019;5:37&#x2013;44. doi: 10.1016/j.coemr.2019.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coemr.2019.02.002</ArticleId><ArticleId IdType="pmc">PMC6690794</ArticleId><ArticleId IdType="pubmed">31406949</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang H, et al. PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve. 2011;44:947&#x2013;956. doi: 10.1002/mus.22217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22217</ArticleId><ArticleId IdType="pubmed">22102466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, et al. Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1a) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener. 2011;6:1&#x2013;8. doi: 10.1186/1750-1326-6-51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-51</ArticleId><ArticleId IdType="pmc">PMC3156746</ArticleId><ArticleId IdType="pubmed">21771318</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S, et al. Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab. 2012;15:778&#x2013;786. doi: 10.1016/j.cmet.2012.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.03.019</ArticleId><ArticleId IdType="pmc">PMC3565468</ArticleId><ArticleId IdType="pubmed">22560226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, et al. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proc Natl Acad Sci USA. 2015;112:E6993&#x2013;7002. doi: 10.1073/pnas.1520639112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1520639112</ArticleId><ArticleId IdType="pmc">PMC4687558</ArticleId><ArticleId IdType="pubmed">26621731</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutz B, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005;25:7805&#x2013;7812. doi: 10.1523/JNEUROSCI.2038-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2038-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725264</ArticleId><ArticleId IdType="pubmed">16120782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2005;191:331&#x2013;336. doi: 10.1016/j.expneurol.2004.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2004.10.007</ArticleId><ArticleId IdType="pubmed">15649489</ArticleId></ArticleIdList></Reference><Reference><Citation>Joardar A, et al. PPAR gamma activation is neuroprotective in a drosophila model of ALS based on TDP-43. Hum Mol Genet. 2015;24:1741&#x2013;1754. doi: 10.1093/hmg/ddu587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu587</ArticleId><ArticleId IdType="pmc">PMC4381760</ArticleId><ArticleId IdType="pubmed">25432537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercruysse P, et al. Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain. 2016;139:1106&#x2013;1122. doi: 10.1093/brain/aww004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww004</ArticleId><ArticleId IdType="pubmed">26984187</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, et al. Nutritional status and risk of amyotrophic lateral sclerosis in Japan. Amyotroph Lateral Scler. 2007;8:300&#x2013;304. doi: 10.1080/17482960701472249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701472249</ArticleId><ArticleId IdType="pubmed">17852010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, et al. Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival. J Neurol. 2016;263:1593&#x2013;1603. doi: 10.1007/s00415-016-8168-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8168-2</ArticleId><ArticleId IdType="pubmed">27260291</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, et al. Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2007;78:367&#x2013;371. doi: 10.1136/jnnp.2005.083378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.083378</ArticleId><ArticleId IdType="pmc">PMC2077791</ArticleId><ArticleId IdType="pubmed">16648143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald KC, et al. Dietary omega-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:1102&#x2013;1110. doi: 10.1001/jamaneurol.2014.1214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1214</ArticleId><ArticleId IdType="pmc">PMC4160351</ArticleId><ArticleId IdType="pubmed">25023276</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelmach-Mardas M, et al. Link between food energy density and body weight changes in obese adults. Nutrients. 2016;8:229. doi: 10.3390/nu8040229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu8040229</ArticleId><ArticleId IdType="pmc">PMC4848697</ArticleId><ArticleId IdType="pubmed">27104562</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergani A, et al. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J Lipid Res. 2007;48:1571&#x2013;1580. doi: 10.1194/jlr.M700017-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M700017-JLR200</ArticleId><ArticleId IdType="pmc">PMC1974855</ArticleId><ArticleId IdType="pubmed">17438338</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Sui Y, Gao W, Cai B, Fan D. Effects of diet on adenosine monophosphate-activated protein kinase activity and disease progression in an amyotrophic lateral sclerosis model. J Int Med Res. 2015;43:67&#x2013;79. doi: 10.1177/0300060514554725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060514554725</ArticleId><ArticleId IdType="pubmed">25534414</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamadeh MJ, Rodriguez MC, Kaczor JJ, Tarnopolsky MA. Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve. 2005;31:214&#x2013;220. doi: 10.1002/mus.20255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20255</ArticleId><ArticleId IdType="pubmed">15625688</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan KS, Halang L, Woods I, Prehn JH. A high-fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43A315T mutant C57BL6/J mice. Dis Model Mech. 2016;9:1029&#x2013;1037. doi: 10.1242/dmm.024786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.024786</ArticleId><ArticleId IdType="pmc">PMC5047697</ArticleId><ArticleId IdType="pubmed">27491077</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, et al. Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020;91:1007&#x2013;1009. doi: 10.1136/jnnp-2020-323372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323372</ArticleId><ArticleId IdType="pubmed">32788256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2020;87:206&#x2013;216. doi: 10.1002/ana.25661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25661</ArticleId><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, et al. Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neurosci Lett. 2007;413:265&#x2013;269. doi: 10.1016/j.neulet.2006.11.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.11.058</ArticleId><ArticleId IdType="pubmed">17174029</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito E, et al. Antioxidant strategies based on tomato-enriched food or pyruvate do not affect disease onset and survival in an animal model of amyotrophic lateral sclerosis. Brain Res. 2007;1168:90&#x2013;96. doi: 10.1016/j.brainres.2007.06.095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.06.095</ArticleId><ArticleId IdType="pubmed">17706944</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E, et al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS One. 2012;7:e34776. doi: 10.1371/journal.pone.0034776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034776</ArticleId><ArticleId IdType="pmc">PMC3318006</ArticleId><ArticleId IdType="pubmed">22509356</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowis K, Banga S. The potential health benefits of the ketogenic diet: a narrative review. Nutrients. 2021;13. 10.3390/nu1305165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8153354</ArticleId><ArticleId IdType="pubmed">34068325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29. doi: 10.1186/1471-2202-7-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-7-29</ArticleId><ArticleId IdType="pmc">PMC1488864</ArticleId><ArticleId IdType="pubmed">16584562</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera TW, et al. Triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis. PLoS One. 2016;11:e0161816. doi: 10.1371/journal.pone.0161816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0161816</ArticleId><ArticleId IdType="pmc">PMC5001695</ArticleId><ArticleId IdType="pubmed">27564703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, et al. Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PLoS One. 2012;7:e49191. doi: 10.1371/journal.pone.0049191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049191</ArticleId><ArticleId IdType="pmc">PMC3492315</ArticleId><ArticleId IdType="pubmed">23145119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kira Y, Nishikawa M, Ochi A, Sato E, Inoue M. L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res. 2006;1070:206&#x2013;214. doi: 10.1016/j.brainres.2005.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.11.052</ArticleId><ArticleId IdType="pubmed">16412993</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:397&#x2013;405. doi: 10.3109/21678421.2013.764568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.764568</ArticleId><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordet T, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007;322:709&#x2013;720. doi: 10.1124/jpet.107.123000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.107.123000</ArticleId><ArticleId IdType="pubmed">17496168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunyach C, et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology. 2012;62:2346&#x2013;2352. doi: 10.1016/j.neuropharm.2012.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2012.02.013</ArticleId><ArticleId IdType="pubmed">22369784</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YM, et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013;12:713&#x2013;726. doi: 10.1016/j.stem.2013.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.04.003</ArticleId><ArticleId IdType="pmc">PMC3707511</ArticleId><ArticleId IdType="pubmed">23602540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014;21:529&#x2013;536. doi: 10.1111/ene.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RN, Agharkar AS, Gonzales EB. A review of creatine supplementation in age-related diseases: more than a supplement for athletes. F1000Res. 2014;3:222. 10.12688/f1000research.5218.1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304302</ArticleId><ArticleId IdType="pubmed">25664170</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne SE, et al. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis. 2006;22:599&#x2013;610. doi: 10.1016/j.nbd.2006.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.01.001</ArticleId><ArticleId IdType="pubmed">16616851</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi P, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature. 1999;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10086395</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld GJ, et al. A randomized sequential trial of creatinein amyotrophic lateral sclerosis. Ann Neurol. 2003;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. A clinical trial of creatine in ALS. 2004;63(9):1656&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534251</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J, et al. Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. 2008;9:266&#x2013;272. doi: 10.1080/17482960802028890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802028890</ArticleId><ArticleId IdType="pmc">PMC2631354</ArticleId><ArticleId IdType="pubmed">18608103</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson J, et al. Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett. 2007;420:128&#x2013;132. doi: 10.1016/j.neulet.2007.03.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2007.03.066</ArticleId><ArticleId IdType="pubmed">17543992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunnane SC, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19:609&#x2013;633. doi: 10.1038/s41573-020-0072-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0072-x</ArticleId><ArticleId IdType="pmc">PMC7948516</ArticleId><ArticleId IdType="pubmed">32709961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>